<DOC>
	<DOCNO>NCT01167257</DOCNO>
	<brief_summary>Overactive bladder ( OAB ) bother symptom syndrome . Traditional medication OAB antimuscarinic agent . However , adverse event dry mouth , constipation , blur vision , dizziness may prohibit patient take drug OAB . Intravesical botulinum toxin A ( BoNT-A ) novel treatment however , BoNT-A cause acute urinary retention large postvoid residual . In grant evaluate liquid liposome delivery BoNT-A ( Liposome encapsulate BoNT-A ) bladder without need cystoscopic-guided needle injection refractory OAB .</brief_summary>
	<brief_title>Effects Safety Liposome Encapsulated Botulinum Toxin A Overactive Bladder Syndrome</brief_title>
	<detailed_description>Overactive bladder ( OAB ) symptom syndrome characterized urgency frequency without urgency incontinence , usually metabolic anatomical disorder find may great impact quality life . Traditional medication OAB antimuscarinic agent target muscarinic receptor . There several adverse event dry mouth , constipation , blur vision , dizziness related antimuscarinics , therefore , patient tolerate treatment . Intravesical botulinum toxin A ( BoNT-A ) recently emerge novel treatment OAB refractory antimuscarinics , however , BoNT-A injection cause acute urinary retention large postvoid residual . Urinary tract infection usually occur follow large postvoid residual urinary retention . If deliver BoNT-A urothelium suburothelial space , detrusor layer , might therapeutic effect urothelial sensory nerve without compromise detrusor contractility . This treatment enable u prevent undesired detrusor underactivity BoNT-A injection , especially elderly patient impair detrusor contractility OAB . Liposomes vesicle , compose concentric phospholipid bilayers separate aqueous compartment . Because liposomes adsorb cell surface fuse cell , use vehicle drug delivery gene therapy . In grant evaluate liquid liposome delivery BoNT-A ( Liposome encapsulate BoNT-A ) bladder without need cystoscopic-guided needle injection refractory OAB , study mechanism action intravesical liposomal drug delivery . If successful , leverage technology transfer expertise bring science bench top bed side apply physician sponsor Investigational New Drug ( IND ) trial use liposome-BoNT patient OAB DO .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1 . Adults age 20 year old 2 . Patients symptoms urgency frequency and/or urge incontinence urgency severity scale ( USS ) least 2 , without urodynamically prove detrusor overactivity ( DO ) ( define International Continence Society ( ICS ) recommendation : spontaneous detrusor contraction occur bladder fill phase occur uninhibited detrusor contraction void bladder capacity urodynamic study ) 3 . Free active urinary tract infection 4 . Free bladder outlet obstruction enrollment 5 . Free overt neurogenic bladder dysfunction 6 . Having treat antimuscarinic agent least 4 week without effect intolerable adverse effect 7 . Patient treat bladder surgery OAB , enterocystoplasty , might affect therapeutic effect test drug 8 . Patient record void diary urinary frequency urgency 9 . Patient his/her legally acceptable representative sign write informed consent form 1 . Use antimuscarinic agent effective treatment low urinary tract symptom 2 . Patients severe cardiopulmonary disease congestive heart failure , arrhythmia , poorly control hypertension , able receive regular followup 3 . Patients bladder outlet obstruction enrollment 4 . Patients postvoid residual &gt; 150 mL 5 . Patients uncontrolled confirmed diagnosis acute urinary tract infection 6 . Patients laboratory abnormality screen include : Alanine aminotransferase ( ALT ) &gt; 3 x upper limit normal range Aspartate aminotransferase ( AST ) &gt; 3 x upper limit normal range Patients abnormal serum creatinine level &gt; 2 x upper limit normal range 7 . Patients contraindication urethral catheterization treatment 8 . Female patient pregnant , lactating , childbearing potential without contraception . 9 . Myasthenia gravis , Eaton Lambert syndrome . 10 . Patients serious disease consider investigator suitable general anesthesia condition enter trial 11 . Patients participate investigational drug trial within 1 month enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Overactive bladder</keyword>
	<keyword>Detrusor overactivity</keyword>
	<keyword>Liposome</keyword>
	<keyword>Botulinum toxin A</keyword>
</DOC>